| NCT ID | NCT07814157 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Basel, Switzerland |
| Condition | Coronary Artery Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2025-10-01 |
| Primary Completion | 2035-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2025-10-01 with a primary completion date of 2035-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This registry aims to learn more about the best ways to treat coronary artery disease. Information from routine medical care will be collected to compare different treatment approaches, including drug-eluting stents, drug-coated balloons (DCB), and bioresorbable scaffolds (BRS), which gradually dissolve over time. The registry will include people with coronary artery disease who receive an intervention (percutaneous coronary intervention), including those undergoing more complex procedures. By studying treatment outcomes over time, the Registry aims to better understand which therapies work best for different groups of patients and to improve future care for people with coronary artery disease.
Eligibility Criteria
Inclusion Criteria: Patients treated at the University Hospital Basel * Undergoing complex PCI (e.g. left main, bifurcation, multivessel PCI, rotational atherectomy or other calcium modification, complex anatomy). The definition complex will be a clinical/ procedural/ anatomical definition made by the operator. * Undergoing CTO or CHIP (Complex High-risk Indicated Patient) procedures * Treated with a DCB strategy * Treated with a BRS Exclusion Criteria: * Patients under 18 years of age
Contact & Investigator
Gregor Leibundgut, Prof. Dr. med.
PRINCIPAL INVESTIGATOR
University Hospital, Basel, Switzerland
Frequently Asked Questions
Who can join the NCT07814157 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Coronary Artery Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07814157 currently recruiting?
Yes, NCT07814157 is actively recruiting participants. Contact the research team at gregor.leibundgut@usb.ch for enrollment information.
Where is the NCT07814157 trial being conducted?
This trial is being conducted at Basel, Switzerland.
Who is sponsoring the NCT07814157 clinical trial?
NCT07814157 is sponsored by University Hospital, Basel, Switzerland. The principal investigator is Gregor Leibundgut, Prof. Dr. med. at University Hospital, Basel, Switzerland. The trial plans to enroll 10,000 participants.